- Home
- URGN vs FIP Comparison
URGN vs FIP Comparison
Compare URGN & FIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- FIP
- Stock Information
- Founded
- URGN 2004
- FIP 2021
- Country
- URGN United States
- FIP United States
- Employees
- URGN N/A
- FIP N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- FIP Consumer Electronics/Appliances
- Sector
- URGN Health Care
- FIP Industrials
- Exchange
- URGN Nasdaq
- FIP Nasdaq
- Market Cap
- URGN 904.0M
- FIP 822.8M
- IPO Year
- URGN 2017
- FIP N/A
- Fundamental
- Price
- URGN $18.94
- FIP $4.46
- Analyst Decision
- URGN Strong Buy
- FIP Buy
- Analyst Count
- URGN 8
- FIP 1
- Target Price
- URGN $28.50
- FIP $12.00
- AVG Volume (30 Days)
- URGN 1.1M
- FIP 2.7M
- Earning Date
- URGN 11-05-2025
- FIP 10-29-2025
- Dividend Yield
- URGN N/A
- FIP 2.72%
- EPS Growth
- URGN N/A
- FIP N/A
- EPS
- URGN N/A
- FIP N/A
- Revenue
- URGN $94,238,000.00
- FIP $382,522,000.00
- Revenue This Year
- URGN $35.60
- FIP $60.89
- Revenue Next Year
- URGN $129.54
- FIP $36.62
- P/E Ratio
- URGN N/A
- FIP N/A
- Revenue Growth
- URGN 10.85
- FIP 16.07
- 52 Week Low
- URGN $3.42
- FIP $3.10
- 52 Week High
- URGN $21.71
- FIP $9.96
- Technical
- Relative Strength Index (RSI)
- URGN 49.18
- FIP 41.89
- Support Level
- URGN $18.45
- FIP $3.90
- Resistance Level
- URGN $21.71
- FIP $4.54
- Average True Range (ATR)
- URGN 1.18
- FIP 0.29
- MACD
- URGN -0.17
- FIP 0.03
- Stochastic Oscillator
- URGN 20.90
- FIP 33.54
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About FIP FTAI Infrastructure Inc.
FTAI Infrastructure Inc is engaged in five segments; Railroad segment includes five freight railroads and one switching company that provide rail service to certain manufacturing and production facilities, the Jefferson Terminal segment consists of a multi-modal crude oil and refined products terminal and other related assets. Repauno segment consists of a 1,630-acre deep-water port located along the Delaware River with an underground storage cavern, a new multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities. Power and Gas segment is comprised of an equity method investment in Long Ridge, and Sustainability and Energy Transition segment is comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.